15 Clinical Trials

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and...

Interventional / Active / NCT02658890

CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma

This randomized phase II trial studies how well DEC-205/NY-ESO-1 fusion protein CDX-1401 (CDX-1401) and neoantigen-based melanoma-poly-ICLC vaccine (poly-ICLC) vaccine therapy work when given with or without recombinant flt3 ligand (CDX-301) in treating patients with stage...

Interventional / Active / NCT02129075

Pembrolizumab and EDP1503 in Advanced Melanoma

This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma. The study will involve initial administration of EDP1503 for a...

Interventional / Active / NCT03595683

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and anti-CTLA4 (ipilimumab) antibodies in advanced melanoma. The study will determine the response rate of the combination and evaluate other clinical parameters such as...

Interventional / Active / NCT02743819

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.

Interventional / Active / NCT02388906

Commonly Searched Clinical Trials

Please note that acceptance into any study is dependent on full clinical evaluation as well as details of study status, both of which can only be fully evaluated at the time of a formal visit and screening.